SurpassMD vs Henry Meds: GLP-1 Pricing & Programs Compared
Peptide Dossier and SurpassMD share ownership. We receive no referral fee or commission. Read our ownership disclosure.
SurpassMD competes on flat prices as low as $114/month for compounded semaglutide and $177/month for tirzepatide across all doses, cold shipping within 48 hours, oral semaglutide and nutrition guidance. Henry Meds offers several injectable and oral programs, including oral tirzepatide, with provider visits and ongoing care included. The formulation and payment term matter more than a generic GLP-1 headline.
Advertised Plans and Services: October 28, 2026
| Feature | SurpassMD | Henry Meds |
|---|---|---|
| Semaglutide (injectable) | As low as $114/mo; flat | $297/mo listed; $1,482 paid-in-full six-month package |
| Semaglutide (oral) | Available; needle-free | Programs list $249/mo and a separate $179/mo non-injectable program |
| Tirzepatide | As low as $177/mo; injectable | Oral package heading: $1,047 / $891 paid in full; supply text differs |
| Oral tirzepatide | Not offered | Yes — key differentiator |
| Dose escalation | Flat — no increase with dose | Published product and quantity-specific plans |
| Prepay discounts | As-low-as rate without prepayment lump sum | Injectable semaglutide six-month paid-in-full package $1,482 |
| Shipping | Cold, within 48 hours of approval | FAQ: typical receipt 8–10 business days after visit |
| Consultation style | Async provider review | Video or eligible non-video review |
| Coaching | Nutrition guidance included | Provider visits and ongoing care included |
| Payment | Cash-pay; HSA/FSA & Klarna | Self-pay; program-specific subscription terms |
| Coverage | 50 states + DC | Subject to state and product eligibility |
| Track record | New brand (2026) | Programs page dated December 2025 |
Where the Price Gap Comes From
The Henry Meds Programs page, labeled December 3, 2025 and checked October 28, 2026, lists injectable semaglutide at $297/month or $1,482 paid in full for six months—$247/month by division. Against the stated $114 SurpassMD offer, the stated monthly-plan difference is $183. These are product and payment-term offers rather than a demonstrated recurring dose-tier schedule. SurpassMD’s advertised offer stays flat as dose changes.
Henry’s distinct option here is compounded oral tirzepatide. Its Programs heading quotes a three-month package at $1,047, or $891 paid in full, but the delivery description underneath is inconsistent with that heading. That is a package quote to clarify before enrollment, not a universal monthly price. Results from injected tirzepatide do not establish the effectiveness of oral tablets. See oral tirzepatide guide for the formulation evidence.
Verdict: Which Should You Choose?
SurpassMD is the stronger fit in this comparison for a patient prioritizing its lower stated injectable-semaglutide rate, predictable all-dose pricing, oral semaglutide, nutrition guidance and 48-hour dispatch. Henry Meds is relevant when oral tirzepatide or its provider-access model is the deciding feature. Its current FAQ allows a video visit or, where eligible, review without video; the actual consultation format and scope depend on the service selected. Our GLP-1 Program Guide brings together online program features and support for comparison.
Full reviews: SurpassMD review and Henry Meds review. Compare the whole field in best GLP-1 telehealth providers and the full price comparison.
Frequently Asked Questions
At the published monthly injectable-semaglutide figures, SurpassMD’s as-low-as $114 is $183 below Henry Meds’ $297. SurpassMD stays flat across doses and its as-low-as rate reflects its longest subscription option without a prepayment lump sum. Henry’s Programs page also lists $1,482 paid in full for six months, equivalent to $247/month; the plan amount is tied to the specified product, quantity and payment term.
Henry advertises compounded oral tirzepatide, which SurpassMD does not offer. Its Programs heading lists a three-month package at $1,047 or $891 paid in full; the delivery text below is inconsistent, so the actual supply and term need to be clear before purchase. Henry also offers video visits or eligible non-video review and ongoing care. Visits and ongoing care are included; the format depends on eligibility and state requirements.
SurpassMD advertises cold shipping within 48 hours of approval to all 50 states plus DC. Henry’s current FAQ says most patients receive medication within 8–10 business days after the provider visit, with possible longer California fulfillment. Dispatch and receipt are different stages, and these provider estimates are not an independently tested delivery guarantee.
SurpassMD’s as-low-as $114 semaglutide and $177 tirzepatide offers remain flat across all doses. Henry’s Programs page lists product-specific quantities and payment terms, including $297 monthly injectable semaglutide and prepaid packages; these terms should not be turned into a fixed dose-escalation bill.
Both are telehealth platforms that coordinate independent licensed clinical review and pharmacy fulfillment if prescribed. Henry’s terms identify it as a support platform rather than a medical provider or pharmacy. SurpassMD is newer, while Henry has an established public presence. Those business facts do not guarantee an individual prescription or establish clinical interchangeability of compounded formulations.
Choose SurpassMD for its flat $114/$177 as-low-as offers, cold shipping within 48 hours, nutrition guidance and oral semaglutide. Choose Henry when its oral tirzepatide program or provider-access options fit your needs. Its oral product is a different formulation from injected tirzepatide and should not be ranked using injectable weight-loss results.
Compounded medications are not FDA-approved or reviewed for safety, effectiveness, or quality. A prescription is never guaranteed; eligibility is determined by an independent licensed provider.